Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.89
BRKR's Cash-to-Debt is ranked lower than
66% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. BRKR: 0.89 )
Ranked among companies with meaningful Cash-to-Debt only.
BRKR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 1.32 Max: 9.3
Current: 0.89
0.13
9.3
Equity-to-Asset 0.37
BRKR's Equity-to-Asset is ranked lower than
78% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BRKR: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
BRKR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.41 Max: 0.69
Current: 0.37
0.14
0.69
Debt-to-Equity 0.66
BRKR's Debt-to-Equity is ranked lower than
66% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. BRKR: 0.66 )
Ranked among companies with meaningful Debt-to-Equity only.
BRKR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 0.41 Max: 1.72
Current: 0.66
0.07
1.72
Debt-to-EBITDA 1.76
BRKR's Debt-to-EBITDA is ranked higher than
51% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. BRKR: 1.76 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BRKR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.25  Med: 1.58 Max: 2.04
Current: 1.76
0.25
2.04
Interest Coverage 13.55
BRKR's Interest Coverage is ranked lower than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. BRKR: 13.55 )
Ranked among companies with meaningful Interest Coverage only.
BRKR' s Interest Coverage Range Over the Past 10 Years
Min: 7.92  Med: 12.32 Max: 59.87
Current: 13.55
7.92
59.87
Piotroski F-Score: 7
Altman Z-Score: 4.19
Beneish M-Score: -2.27
WACC vs ROIC
9.76%
22.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 11.60
BRKR's Operating Margin % is ranked higher than
72% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BRKR: 11.60 )
Ranked among companies with meaningful Operating Margin % only.
BRKR' s Operating Margin % Range Over the Past 10 Years
Min: 5.83  Med: 9.6 Max: 13.34
Current: 11.6
5.83
13.34
Net Margin % 8.85
BRKR's Net Margin % is ranked higher than
79% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. BRKR: 8.85 )
Ranked among companies with meaningful Net Margin % only.
BRKR' s Net Margin % Range Over the Past 10 Years
Min: 3.13  Med: 6.06 Max: 9.58
Current: 8.85
3.13
9.58
ROE % 21.02
BRKR's ROE % is ranked higher than
90% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. BRKR: 21.02 )
Ranked among companies with meaningful ROE % only.
BRKR' s ROE % Range Over the Past 10 Years
Min: 7.03  Med: 14.91 Max: 23.93
Current: 21.02
7.03
23.93
ROA % 8.10
BRKR's ROA % is ranked higher than
84% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. BRKR: 8.10 )
Ranked among companies with meaningful ROA % only.
BRKR' s ROA % Range Over the Past 10 Years
Min: 2.94  Med: 5.66 Max: 11.34
Current: 8.1
2.94
11.34
ROC (Joel Greenblatt) % 37.22
BRKR's ROC (Joel Greenblatt) % is ranked higher than
78% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. BRKR: 37.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BRKR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 19.4  Med: 30.31 Max: 54.93
Current: 37.22
19.4
54.93
3-Year Revenue Growth Rate -3.10
BRKR's 3-Year Revenue Growth Rate is ranked lower than
70% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. BRKR: -3.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BRKR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.75 Max: 43.4
Current: -3.1
0
43.4
3-Year EBITDA Growth Rate 8.50
BRKR's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. BRKR: 8.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BRKR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.45 Max: 145.1
Current: 8.5
0
145.1
3-Year EPS without NRI Growth Rate 25.60
BRKR's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. BRKR: 25.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BRKR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.1 Max: 59.6
Current: 25.6
0
59.6
GuruFocus has detected 6 Warning Signs with Bruker Corp BRKR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BRKR's 30-Y Financials

Financials (Next Earnings Date: 2018-02-13)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BRKR Guru Trades in Q4 2016

Steven Cohen 48,800 sh (New)
Joel Greenblatt 13,320 sh (New)
Murray Stahl 19,630 sh (+6.98%)
NWQ Managers 394,886 sh (-1.71%)
Jim Simons 28,610 sh (-93.34%)
» More
Q1 2017

BRKR Guru Trades in Q1 2017

Paul Tudor Jones 15,738 sh (New)
Steven Cohen 1,152,600 sh (+2261.89%)
Joel Greenblatt 48,721 sh (+265.77%)
Jim Simons 59,110 sh (+106.61%)
NWQ Managers Sold Out
Murray Stahl 17,741 sh (-9.62%)
» More
Q2 2017

BRKR Guru Trades in Q2 2017

George Soros 19,100 sh (New)
Jim Simons 170,710 sh (+188.80%)
Joel Greenblatt 77,652 sh (+59.38%)
Paul Tudor Jones 15,980 sh (+1.54%)
Murray Stahl 14,377 sh (-18.96%)
Steven Cohen 616,600 sh (-46.50%)
» More
Q3 2017

BRKR Guru Trades in Q3 2017

Ken Fisher 148,000 sh (New)
Jeremy Grantham 10,600 sh (New)
Steven Cohen 667,400 sh (+8.24%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
George Soros Sold Out
Murray Stahl 13,247 sh (-7.86%)
Jim Simons 127,710 sh (-25.19%)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 New Buy0.01%$27.07 - $30.12 $ 33.7417%148,000
Joel Greenblatt 2017-09-30 Sold Out 0.03%$27.07 - $30.12 $ 33.7417%0
George Soros 2017-09-30 Sold Out 0.01%$27.07 - $30.12 $ 33.7417%0
Joel Greenblatt 2017-06-30 Add 59.38%0.01%$21.9 - $29.98 $ 33.7431%77,652
George Soros 2017-06-30 New Buy0.01%$21.9 - $29.98 $ 33.7431%19,100
Joel Greenblatt 2017-03-31 Add 265.77%0.01%$21.58 - $25.1 $ 33.7444%48,721
NWQ Managers 2017-03-31 Sold Out 0.11%$21.58 - $25.1 $ 33.7444%0
NWQ Managers 2016-12-31 Reduce -1.71%$19.87 - $23.3 $ 33.7454%394,886
Joel Greenblatt 2016-12-31 New Buy$19.87 - $23.3 $ 33.7454%13,320
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:MIL:DIA, XTER:AFX, NAS:PRAH, NAS:PRXL, NYSE:ALR, NYSE:CRL, NAS:VWR, NAS:INCR, NAS:EXAS, NAS:DXCM, XTER:SRT3, NAS:ICLR, NYSE:BIO, SHSE:603658, NAS:NEOG, BSP:FLRY3, TSE:4544, BSP:DASA3, NAS:MYGN, SZSE:300244 » details
Traded in other countries:BKD.Germany,
Headquarter Location:USA
Bruker Corp is a developer, manufacturer and distributor of scientific instruments and analytical and dignostic solutions that enable customers to explore life and materials at microscopic, molecular and cellular levels.

Bruker Corp is a developer, manufacturer and distributor of scientific instruments and analytical and dignostic solutions that enable customers to explore life and materials at microscopic, molecular and cellular levels.

Ratios

vs
industry
vs
history
PE Ratio 35.88
BRKR's PE Ratio is ranked higher than
62% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. BRKR: 35.88 )
Ranked among companies with meaningful PE Ratio only.
BRKR' s PE Ratio Range Over the Past 10 Years
Min: 7.21  Med: 29.51 Max: 67.25
Current: 35.88
7.21
67.25
Forward PE Ratio 24.69
BRKR's Forward PE Ratio is ranked lower than
58% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. BRKR: 24.69 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 35.88
BRKR's PE Ratio without NRI is ranked higher than
64% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. BRKR: 35.88 )
Ranked among companies with meaningful PE Ratio without NRI only.
BRKR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.21  Med: 29.51 Max: 67.25
Current: 35.88
7.21
67.25
Price-to-Owner-Earnings 59.00
BRKR's Price-to-Owner-Earnings is ranked lower than
67% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. BRKR: 59.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BRKR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.85  Med: 43.08 Max: 6933.33
Current: 59
10.85
6933.33
PB Ratio 7.33
BRKR's PB Ratio is ranked lower than
70% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. BRKR: 7.33 )
Ranked among companies with meaningful PB Ratio only.
BRKR' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 4.5 Max: 8.92
Current: 7.33
1.61
8.92
PS Ratio 3.20
BRKR's PS Ratio is ranked higher than
62% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. BRKR: 3.20 )
Ranked among companies with meaningful PS Ratio only.
BRKR' s PS Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.86 Max: 3.2
Current: 3.2
0.5
3.2
Price-to-Free-Cash-Flow 54.61
BRKR's Price-to-Free-Cash-Flow is ranked lower than
74% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. BRKR: 54.61 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BRKR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.25  Med: 29.85 Max: 147.38
Current: 54.61
10.25
147.38
Price-to-Operating-Cash-Flow 38.20
BRKR's Price-to-Operating-Cash-Flow is ranked lower than
73% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. BRKR: 38.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BRKR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.71  Med: 21.02 Max: 50.96
Current: 38.2
5.71
50.96
EV-to-EBIT 25.10
BRKR's EV-to-EBIT is ranked higher than
62% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. BRKR: 25.10 )
Ranked among companies with meaningful EV-to-EBIT only.
BRKR' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 20 Max: 36.2
Current: 25.1
5.2
36.2
EV-to-EBITDA 19.43
BRKR's EV-to-EBITDA is ranked higher than
60% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. BRKR: 19.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
BRKR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.7  Med: 16 Max: 36.2
Current: 19.43
4.7
36.2
EV-to-Revenue 3.13
BRKR's EV-to-Revenue is ranked higher than
65% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. BRKR: 3.13 )
Ranked among companies with meaningful EV-to-Revenue only.
BRKR' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.6  Med: 1.8 Max: 3.4
Current: 3.13
0.6
3.4
PEG Ratio 20.29
BRKR's PEG Ratio is ranked lower than
91% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.98 vs. BRKR: 20.29 )
Ranked among companies with meaningful PEG Ratio only.
BRKR' s PEG Ratio Range Over the Past 10 Years
Min: 0.09  Med: 1.29 Max: 23.94
Current: 20.29
0.09
23.94
Shiller PE Ratio 54.37
BRKR's Shiller PE Ratio is ranked higher than
54% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. BRKR: 54.37 )
Ranked among companies with meaningful Shiller PE Ratio only.
BRKR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 34.62  Med: 47.61 Max: 96.73
Current: 54.37
34.62
96.73
Current Ratio 2.60
BRKR's Current Ratio is ranked higher than
52% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. BRKR: 2.60 )
Ranked among companies with meaningful Current Ratio only.
BRKR' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.21 Max: 4.99
Current: 2.6
1.26
4.99
Quick Ratio 1.60
BRKR's Quick Ratio is ranked lower than
63% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BRKR: 1.60 )
Ranked among companies with meaningful Quick Ratio only.
BRKR' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.3 Max: 3.95
Current: 1.6
0.43
3.95
Days Inventory 190.49
BRKR's Days Inventory is ranked lower than
87% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. BRKR: 190.49 )
Ranked among companies with meaningful Days Inventory only.
BRKR' s Days Inventory Range Over the Past 10 Years
Min: 179.35  Med: 216.33 Max: 264.16
Current: 190.49
179.35
264.16
Days Sales Outstanding 57.73
BRKR's Days Sales Outstanding is ranked higher than
64% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. BRKR: 57.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRKR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.76  Med: 59.73 Max: 65.48
Current: 57.73
52.76
65.48
Days Payable 37.31
BRKR's Days Payable is ranked lower than
68% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. BRKR: 37.31 )
Ranked among companies with meaningful Days Payable only.
BRKR' s Days Payable Range Over the Past 10 Years
Min: 26.4  Med: 29.9 Max: 147.25
Current: 37.31
26.4
147.25

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.48
BRKR's Dividend Yield % is ranked lower than
69% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.89 vs. BRKR: 0.48 )
Ranked among companies with meaningful Dividend Yield % only.
BRKR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.14  Med: 0.54 Max: 0.76
Current: 0.48
0.14
0.76
Dividend Payout Ratio 0.17
BRKR's Dividend Payout Ratio is ranked higher than
77% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 0.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BRKR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.17  Med: 0.17 Max: 0.17
Current: 0.17
Forward Dividend Yield % 0.48
BRKR's Forward Dividend Yield % is ranked lower than
73% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. BRKR: 0.48 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.48
BRKR's 5-Year Yield-on-Cost % is ranked lower than
80% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. BRKR: 0.48 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BRKR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14  Med: 0.54 Max: 0.76
Current: 0.48
0.14
0.76
3-Year Average Share Buyback Ratio 1.60
BRKR's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. BRKR: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BRKR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.1  Med: -5.85 Max: 0
Current: 1.6
-22.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 49.62
BRKR's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.01 vs. BRKR: 49.62 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BRKR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 13.54 Max: 103.75
Current: 49.62
2.43
103.75
Price-to-Tangible-Book 11.25
BRKR's Price-to-Tangible-Book is ranked lower than
76% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.57 vs. BRKR: 11.25 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BRKR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.35  Med: 5.67 Max: 20.43
Current: 11.25
1.35
20.43
Price-to-Intrinsic-Value-Projected-FCF 3.42
BRKR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
59% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. BRKR: 3.42 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BRKR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.91  Med: 2.15 Max: 10.62
Current: 3.42
0.91
10.62
Price-to-Median-PS-Value 1.70
BRKR's Price-to-Median-PS-Value is ranked lower than
77% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BRKR: 1.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BRKR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.96 Max: 9.28
Current: 1.7
0.32
9.28
Price-to-Peter-Lynch-Fair-Value 6.73
BRKR's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. BRKR: 6.73 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BRKR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.46 Max: 13.14
Current: 6.73
0.4
13.14
Price-to-Graham-Number 4.24
BRKR's Price-to-Graham-Number is ranked lower than
58% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.40 vs. BRKR: 4.24 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BRKR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.07  Med: 3.13 Max: 15.92
Current: 4.24
1.07
15.92
Earnings Yield (Greenblatt) % 3.96
BRKR's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. BRKR: 3.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BRKR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 5 Max: 19.4
Current: 3.96
2.8
19.4
Forward Rate of Return (Yacktman) % 7.20
BRKR's Forward Rate of Return (Yacktman) % is ranked lower than
55% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. BRKR: 7.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BRKR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.8  Med: 9.45 Max: 110.4
Current: 7.2
-1.8
110.4

More Statistics

Revenue (TTM) (Mil) $1,705.70
EPS (TTM) $ 0.94
Beta1.30
Short Percentage of Float4.01%
52-Week Range $21.03 - 35.16
Shares Outstanding (Mil)155.56

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,743 1,840 1,913
EPS ($) 1.23 1.35 1.49
EPS without NRI ($) 1.23 1.35 1.49
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.16 0.16 0.16

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}